TN2010000135A1 - Galenical formulations of organic compounds - Google Patents

Galenical formulations of organic compounds

Info

Publication number: TN2010000135A1
Authority: TN; Tunisia
Prior art keywords: minutes; organic compounds; galenical formulations; pharmaceutically acceptable; acceptable salt
Prior art date: 2007-09-28

Application number

TNP2010000135A

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-28

Filing date

2010-03-26

Publication date

2011-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377183&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000135(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-03-26 Application filed by Novartis Ag filed Critical Novartis Ag

2011-09-26 Publication of TN2010000135A1 publication Critical patent/TN2010000135A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TNP2010000135A 2007-09-28 2010-03-26 Galenical formulations of organic compounds TN2010000135A1 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US97591907P	2007-09-28	2007-09-28
US97590107P	2007-09-28	2007-09-28
US97592507P	2007-09-28	2007-09-28
US97590907P	2007-09-28	2007-09-28
PCT/US2008/077416 WO2009045795A2 (fr)	2007-09-28	2008-09-24	Formulations galéniques de composés organiques

Publications (1)

Publication Number	Publication Date
TN2010000135A1 true TN2010000135A1 (en)	2011-09-26

Family

ID=40377183

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2010000135A TN2010000135A1 (en)	2007-09-28	2010-03-26	Galenical formulations of organic compounds

Country Status (18)

Country	Link
US (1)	US20100209480A1 (fr)
EP (1)	EP2205233A2 (fr)
JP (1)	JP2010540547A (fr)
KR (1)	KR20100063090A (fr)
CN (1)	CN101808631A (fr)
AR (1)	AR066168A1 (fr)
AU (1)	AU2008309058B2 (fr)
BR (1)	BRPI0817442A2 (fr)
CA (1)	CA2698330A1 (fr)
CL (1)	CL2008002829A1 (fr)
CO (1)	CO6270217A2 (fr)
EC (1)	ECSP10010052A (fr)
MA (1)	MA31706B1 (fr)
MX (1)	MX2010003441A (fr)
PE (1)	PE20090654A1 (fr)
TN (1)	TN2010000135A1 (fr)
TW (1)	TW200924737A (fr)
WO (1)	WO2009045795A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CL2008002828A1 (es) *	2007-09-28	2009-05-15	Novartis Ag	Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno.
AR073651A1 (es) *	2008-09-24	2010-11-24	Novartis Ag	Formulaciones galenicas de compuestos organicos
KR20110130491A (ko) *	2009-03-20	2011-12-05	노파르티스 아게	발사르탄 및 알리스키렌의 고정 용량 조합물의 생약 제형
US20120003308A1 (en) *	2009-03-20	2012-01-05	Sonali Bose	Pharmaceutical Composition Comprising Aliskiren
WO2011116115A1 (fr) *	2010-03-16	2011-09-22	Novartis Ag	Composition d'aliskiren comprenant un acide gras à chaîne moyenne et procédé de fabrication correspondant
TR201002256A1 (tr) *	2010-03-24	2011-10-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Stabil aliskiren formülasyonları
CN101926793B (zh) *	2010-08-05	2012-08-15	成都自豪药业有限公司	一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
IN2014CN02610A (fr) *	2011-10-12	2015-08-07	Dow Global Technologies Llc
KR20140108652A (ko) *	2011-12-26	2014-09-12	노파르티스 아게	정제 및 건식-코팅된 작용제
CN103349652B (zh) *	2013-05-11	2014-11-19	辽宁大学	含有四氢萘酰胺化合物或其可药用盐的高药物载荷片剂
CN116887866A (zh)	2020-12-03	2023-10-13	巴特尔纪念研究院	聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
AU2022253899A1 (en)	2021-04-07	2023-10-26	Battelle Memorial Institute	Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025072751A1 (fr)	2023-09-29	2025-04-03	Battelle Memorial Institute	Compositions de nanoparticules polymères pour l'expression in vivo de polypeptides
WO2025122954A1 (fr)	2023-12-08	2025-06-12	Battelle Memorial Institute	Utilisation de nanostructures d'origami d'adn pour systèmes de stockage de données basés sur des informations moléculaires

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK469989D0 (da) *	1989-09-22	1989-09-22	Bukh Meditec	Farmaceutisk praeparat
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US6669955B2 (en) *	2001-08-28	2003-12-30	Longwood Pharmaceutical Research, Inc.	Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
MY144477A (en) *	2004-03-17	2011-09-30	Novartis Ag	Galenic formulations of organic compounds
ATE551052T1 (de) *	2004-10-08	2012-04-15	Novartis Ag	Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
MY146830A (en) *	2005-02-11	2012-09-28	Novartis Ag	Combination of organic compounds
CN101166523A (zh) *	2005-04-27	2008-04-23	诺瓦提斯公司	治疗动脉粥样硬化的方法

2008
- 2008-09-24 US US12/678,877 patent/US20100209480A1/en not_active Abandoned
- 2008-09-24 JP JP2010527091A patent/JP2010540547A/ja not_active Withdrawn
- 2008-09-24 WO PCT/US2008/077416 patent/WO2009045795A2/fr not_active Ceased
- 2008-09-24 PE PE2008001660A patent/PE20090654A1/es not_active Application Discontinuation
- 2008-09-24 AU AU2008309058A patent/AU2008309058B2/en not_active Ceased
- 2008-09-24 CA CA2698330A patent/CA2698330A1/fr not_active Abandoned
- 2008-09-24 MX MX2010003441A patent/MX2010003441A/es not_active Application Discontinuation
- 2008-09-24 KR KR1020107006603A patent/KR20100063090A/ko not_active Withdrawn
- 2008-09-24 TW TW097136690A patent/TW200924737A/zh unknown
- 2008-09-24 CN CN200880108860A patent/CN101808631A/zh active Pending
- 2008-09-24 CL CL2008002829A patent/CL2008002829A1/es unknown
- 2008-09-24 EP EP08835022A patent/EP2205233A2/fr not_active Withdrawn
- 2008-09-24 BR BRPI0817442-3A patent/BRPI0817442A2/pt not_active IP Right Cessation
- 2008-09-24 AR ARP080104137A patent/AR066168A1/es not_active Application Discontinuation
2010
- 2010-03-17 MA MA32701A patent/MA31706B1/fr unknown
- 2010-03-26 EC EC2010010052A patent/ECSP10010052A/es unknown
- 2010-03-26 TN TNP2010000135A patent/TN2010000135A1/fr unknown
- 2010-04-19 CO CO10045487A patent/CO6270217A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2698330A1 (fr)	2009-04-09
EP2205233A2 (fr)	2010-07-14
WO2009045795A3 (fr)	2009-07-16
AU2008309058A1 (en)	2009-04-09
WO2009045795A2 (fr)	2009-04-09
AU2008309058B2 (en)	2012-08-09
CO6270217A2 (es)	2011-04-20
US20100209480A1 (en)	2010-08-19
CL2008002829A1 (es)	2009-06-26
KR20100063090A (ko)	2010-06-10
JP2010540547A (ja)	2010-12-24
BRPI0817442A2 (pt)	2015-06-16
TW200924737A (en)	2009-06-16
AR066168A1 (es)	2009-07-29
MX2010003441A (es)	2010-04-21
CN101808631A (zh)	2010-08-18
PE20090654A1 (es)	2009-06-27
MA31706B1 (fr)	2010-09-01
ECSP10010052A (es)	2010-04-30

Publication	Publication Date	Title
TN2010000135A1 (en)	2011-09-26	Galenical formulations of organic compounds
PL2205279T3 (pl)	2011-09-30	Farmaceutyczna kombinacja aliskirenu i walsartanu
MX2012007375A (es)	2012-07-30	3-ceto-n-propargil 1-aminoindano.
UA93709C2 (ru)	2011-03-10	12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2007138466A3 (fr)	2009-04-23	Compositions pharmaceutiques comprenant une combinaison de meloxicam et de tramadol
IL193252A0 (en)	2009-02-11	N-hydroxyacrylamide compounds
MX2009004017A (es)	2009-07-24	Usos de los compuestos carboxi-amido triazol y sus sales.
UA96622C2 (ru)	2011-11-25	Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2007131070A3 (fr)	2008-04-03	Compositions, formes pharmaceutiques et méthodes de traitement des vomissements
SG141358A1 (en)	2008-04-28	Treatment of psychiatric patients with reduced heptaic function with paliperidone
MX2010001243A (es)	2010-03-11	Composicion anti-inflamatoria.
IL187632A (en)	2014-02-27	17 – Ethinyl – 17 – Hydroxy – 13 – Methyl – 17,16,15,14,13,12,11,9,8,7 – Dachahydro – 6 h– Cyclopentane [a] Penanthran – 3 – Ilmethyl ester of acetoxy acid Acetic, a pharmaceutical dosage unit containing it and its use in the preparation of a contraceptive
EP2196463A4 (fr)	2011-08-17	Procédé de préparation d'acide 5,6-diméthylxanthone-acétique, dérivés ainsi obtenus et formulations pharmaceutiques de ceux-ci
UA102111C2 (uk)	2013-06-10	Фармацевтична композиція у вигляді разової пероральної дози, що містить леводопу, карбідопу і ентакапон або їх солі
JO3239B1 (ar)	2018-03-08	تركيبات جالينية من مركبات عضوية
MY148266A (en)	2013-03-29	Galenical formulations of aliskiren
MX2009005804A (es)	2009-09-24	Composicion farmaceutica de memantina.
WO2005120518A3 (fr)	2006-05-26	Utilisation d'analogues d'atp pour le traitement des maladies cardio-vasculaires
MXPA05007253A (es)	2005-12-14	Sales novedosas de derivados anticonvulsivantes.
TN2011000100A1 (en)	2012-09-05	Galenical formulations of organic compounds
MX2011009846A (es)	2011-09-29	Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
ZA201005394B (en)	2014-01-29	15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid y-lactone derivative,use thereof,and medicament containing said derivative
TW200833375A (en)	2008-08-16	Pharmaceutical compositions
WO2010044108A3 (fr)	2010-07-15	Formulations à libération contrôlée de ropinirole
SI1817029T1 (sl)	2010-01-29	Derivati izoksazola za lajĺ anje nevropatskih boleäśin